NATALIZUMAB (TYSABRI®) PRESCRIBER ORDER FORM					
Patient Name:		Date of Birth:	Date of Birth:		
Address:		1			
Patient Phone:	Height:	□ inches □ cn	n Weight:	☐ lbs. ☐ kg	
	Clinical Information				
Primary Diagnosis Description:		ICI	D-10 Code:		
Is this the first dose?					
Natalizumab (Tysabri®) Prescription					
Natalizumab (Tysabri®) 300 mg refill as directed x 1 year					
Infuse 300 mg IV over 60 minutes every 4 weeks.					
Ancillary Orders					
Anaphylaxis Kit Dosage: Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SQ or IM x 1; repeat x 1 in 5 to 15 min PRN. Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg) IV or IM; repeat x 1 in 15 min PRN no improvement. 0.9% Sodium Chloride 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis.					
 □ Acetaminophen 650 mg PO 30 min before infusion, may repeat every 3 to 4 hours as needed for fever or mild discomfort. Patient may decline. □ Diphenhydramine 25 mg PO 30 min before infusion, may repeat every 4 to 6 hours as needed for mild to moderate allergic reactions. Patient may decline. □ Loratadine 10 mg PO 30 min before infusion. Patient may decline. □ Methylprednisolone sodium succinate 40 mg IV push 20 minutes prior to infusion. □ Other: 					
IV Flush Orders Peripheral: NS 2 to 3 mL pre-/post-use. Implanted Port: NS 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed. Lab Orders No labs ordered at this time. Other: Skilled nurse to administer doses intravenously in the home or alternate care setting. Refill above ancillary orders as directed x 1 year.					
I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.					
Prescriber Signature:		Date:			
Prescriber Name:	Prescriber Information Phone	e:	Fax:		
Address: N		NPI:			
City, State:	Zip: Office	Contact:			
Fax completed form, insurance information, and clinical documentation to: CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require					
authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is					

CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.